Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
"As a medicines company, we have delivered more than one million packs of antibiotics, painkillers, cardiovascular, and oncology treatments which amounts to more than USD 25 million in medical aid to maintain the supply to those who rely on these drugs in Ukraine and in the border areas where people are seeking refuge."
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
- Details
- Category: Sanofi
![Sanofi Sanofi](/images/logo/sanofi.png)
Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Novartis announces new organizational structure
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
U.S. FDA grants priority review to Roche's Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
More Pharma News ...
- Roche donates additional medicines and diagnostics for Ukraine
- Pfizer and BioNTech receive expanded U.S. emergency use authorization for an additional COVID-19 vaccine booster in individuals aged 50 years and older
- Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19
- Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries
- Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
- Pfizer and BioNTech aubmit for U.S. Emergency Use Authorization of an additional booster dose of their COVID-19 vaccine for older adults
- Pfizer updates company position in Russia